A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

In a trial, vibegron 75 mg once daily meaningfully improved key OAB symptoms in men receiving benign prostatic hyperplasia treatments. Vibegron reduces storage symptoms of overactive bladder (OAB) in ...

THURSDAY, Jan. 2, 2025 (HealthDay News) -- Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy ...